CollPlant Ltd (CLGN): Price-to-Revenue Ratio

Symbol and logo of brand CollPlant Biotechnologies (CLGN)

The price-to-sales dynamics of CollPlant Biotechnologies (CLGN) reflect current market expectations, where 27.20 represents the latest metric level. The business is shielded from macroeconomic shocks due to stable demand for medical supplies. The company operates its own plant for plant-based collagen synthesis in Israel, while engaging external contractors to conduct clinical trials and implement marketing strategies.

CollPlant Biotechnologies Ltd. (CLGN) - Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for CollPlant Biotechnologies (CLGN)

- current price and projected stock value:
Price Chart collplant.com|CLGN - Price Target Chart
- stock exchange capitalization data:
Market Value CollPlant Ltd|CLGN - Total Company Value
- issuer book value statistics:
Share Book Value CollPlant Biotechnologies|CLGN - Company Book Value|Market Value to Book Value Ratio collplant.com|CLGN - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital CollPlant Biotechnologies|CLGN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio collplant.com|CLGN - Company Total Debt|Debt to Book Capital CollPlant Ltd|CLGN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings CollPlant Biotechnologies|Quick Liquidity collplant.com
- earnings and valuation multiples indicators:
CLGN - Net Profit|Company Profit Forecast CollPlant Biotechnologies|CLGN - Price to Earnings Ratio|Projected Price to Earnings Ratio collplant.com|CLGN - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio CollPlant Ltd|CLGN - Operating profit EBITDA|Net earnings per one share for the last twelve months CollPlant Biotechnologies|CLGN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months collplant.com|CLGN - Earnings growth in current year|Expected earnings per share trend next year CollPlant Biotechnologies
- total revenue and sales volume data:
CLGN - Company Revenue|Company Revenue Forecast collplant.com|CLGN - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio CollPlant Ltd
Summary company analytics:CollPlant
Signature product of CollPlant

CollPlant Biotechnologies (CLGN) holds a leading position in regenerative medicine thanks to its unique 3D bioprinting technologies. By analyzing the price-to-sales ratio, an investor can see the current market capitalization relative to actual revenue volume. This multiple allows for the rapid identification of a "value trap" risk if quotes drop to critical levels. High brand loyalty among medical institutions should support this metric, confirming the fundamental stability of the business.

Who CollPlant Biotechnologies competes with

Price-to-Revenue Ratio HCA (hcahealthcare.com)|Price-to-Revenue Ratio Tenet Healthcare Corporation THC|Fresenius Medical Care AG - Price-to-Revenue Ratio|SOLV - Price-to-Revenue Ratio|Price-to-Sales Ratio EHC|uhsinc.com (UHS) - Price-to-Revenue Ratio|DVA (davita.com) - Price-to-Revenue Ratio|RDNT (RadNet) - P/S Multiple|P/S Multiple Option Care|Price-to-Revenue Ratio Surgery Partners Corp (SGRY)|Premier Health - Market Cap to Revenue Ratio|National Vision Holdings - Market Cap to Revenue|Market Cap to Sales Volume PGNY (progyny.com)|ARDT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SEM (Select Medical Corporation)|ASTH: P/S Multiple|MD (MEDNAX) - Price-to-Revenue Ratio|USPH (US Physical Therapy) - P/S Multiple|pennantgroup.com (PNTG) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Organogenesis (ORGO)|NUTX - Price to Sales|Auna Health - Market Cap to Revenue|Market Cap to Sales Volume SBC (SBC Medical Group Holdings)|Evolus, Inc. - P/S Multiple|Price to Sales chs.net|SKIN: P/S Multiple|Market Cap to Revenue MediWound|BTMD (Biote Corp) - P/S Multiple|JYNT: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio DocGo Inc. (DCGO)|p3hp.org - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Gain Therapeutics GANX|EUDA Health Holdings (EUDA) - Price to Sales|BMGL - Price-to-Revenue Ratio|CUPR: Price-to-Revenue Ratio|Concord Medical Services (CCM) - Price-to-Revenue Ratio|Price to Sales ashs.com (AMS)|MRM (MEDIROM Healthcare Group) - P/S Multiple|ALBT - Price-to-Revenue Multiple|P/S Multiple DHAI|Price-to-Revenue Coefficient Carmell Corp|P/S Multiple NIVF (NewGenIvf Group Limited)|ATI Physical Therapy Inc. (ATIP) - Price to Sales|CMAX - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Kindly MD Inc KDLY|MODV: P/S Multiple|Market Cap to Revenue Novo Integrated Sciences Corp|Price-to-Revenue Ratio SunLink Health Systems Inc.|Price-to-Revenue Ratio BACK